AAPL
40
-5
PSA
58
-2
DFS
73
3
GOOG
75
6
EL
18
3
VMC
62
-3
NWSA
78
-19
KR
50
-2
PEG
62
4
VRTX
62
-6
GM
72
3
AKAM
47
5
INTC
48
5
WHR
72
2
ADI
49
-2
ADSK
75
3
ACN
49
2
AEE
66
6
WY
51
-5
EMN
55
5
AAPL
40
-5
PSA
58
-2
DFS
73
3
GOOG
75
6
EL
18
3
VMC
62
-3
NWSA
78
-19
KR
50
-2
PEG
62
4
VRTX
62
-6
GM
72
3
AKAM
47
5
INTC
48
5
WHR
72
2
ADI
49
-2
ADSK
75
3
ACN
49
2
AEE
66
6
WY
51
-5
EMN
55
5
Financhill
Back

Stereotaxis 10K Form

Sell
32

STXS
Stereotaxis

Last Price:
2.26
Seasonality Move:
7.66%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive STXS News And Ratings

See the #1 stock for the next 7 days that we like better than STXS

STXS Financial Statistics

Sales & Book Value

Annual Sales: $26.77M
Cash Flow: $-3.11M
Price / Cash Flow: 0
Annual Sales: $0.14
Price / Book: 13.79

Profitability

EPS (TTM): -0.26000
Net Income (TTM): $-20.75M
Gross Margin: $14.86M
Return on Equity: -94.33%
Return on Assets: -49.35%

Stereotaxis Earnings Forecast

Key Stereotaxis Financial Ratios

  • The Gross Profit Margin over the past 24 years for STXS is 55.51%.
  • The Selling, General & Administrative Expenses for STXS have been equal to 98.71% of Gross Profit Margin.
  • The Research & Development expenses have been 38.37% of Revenue.
  • The Interest Expense is 16.67% of Operating Income.
  • The Net Earning history of STXS is -77.37% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 13 years.

Stereotaxis Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: STXS
CUSIP: 85916J
Website: stereotaxis.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.29
Quick Ratio: 1.43

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

STXS Technical Analysis vs Fundamental Analysis

Sell
32
Stereotaxis (STXS) is a Sell

Is Stereotaxis a Buy or a Sell?

  • Stereotaxis stock is rated a Sell
    The current Stereotaxis [STXS] share price is $1.85. The Score for STXS is 32, which is 36% below its historic median score of 50, and infers higher risk than normal.